Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

Slides:

Advertisements

Similar presentations

Aromatase inhibitors in pediatrics short stature and delayed puberty.

Advertisements

Date of download: 9/18/2016 From: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial.

ADULT GROWTH HORMONE DEFICIENCY

Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.

Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.

Girl, 13-4/12 years old, with constitutional delay in growth and puberty. History revealed a normal growth rate but short stature at all ages. Physical.

The Effects of Growth Hormone and Sex Steroid on Lean Body Mass, Fat Mass, Muscle Strength, Cardiovascular Endurance and Adverse Events in Healthy Elderly.

Figure 2. Summary of trial events

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

Fig. 1. Baseline and 3-month infusion protocol

Precocious or early puberty in patients with

Fig. 1. Time line for investigations

Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.

Numbers correspond to section of text addressing selected clinical issue. From: Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice.

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs of the FTO gene. The P values are for the additive model.

Fig. 1. Correlation of TSH with TC, LDL-C, HDL-C, and TG.

Fig. 1. Study enrollment and disposition of participants

Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.

Volume 77, Issue 5, Pages (March 2010)

Fig. 1. Left, Total ghrelin; right, octanoylated ghrelin

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1. Consort flow diagram.

Fig. 1. BAT activity before and after WL

Fig. 1. Effect of bariatric surgery on BMI and plasma leptin concentration. BMI (A) and plasma leptin concentrations (B) were determined in 27 morbidly.

Fig. 1. Flow of subjects through different phases of the study.

Quantified net intensity data are in arbitrary units (AU)

Fig. 1. Distribution of tetracycline labels (A) and MS/BS (B) in the TPTD and ZOL acid groups: values are medians (interquartile range). Representative.

with Special Reference to GH

Fig. 1. Active GLP-1 and total PYY in response to a liquid test meal

From: Low Vitamin D Status despite Abundant Sun Exposure

Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.

Fig. 1. Mean plasma lipid and lipoprotein levels as a function of the common genetic variants in LCAT, g.-293G>A, S208T, and L369L in the CCHS and S208T.

Figure 1. Total (A) and free (B) T, estradiol (C), and SHBG (D) levels at baseline and during treatment. From: Testosterone Treatment and Sexual Function.

Fig. 5. Histopathological study of the tumor tissue removed from patient 2. A, Macroscopic view of a tumor slice showing a dense tissue occupying the center.

Figure 1. Analysis of four different hPRLR mRNA isoforms (L, I, S1a, and S1b) in human breast adipose tissue (Breast AT), sc abdominal.

Figure 1. Summary of PTH secretion from human parathyroid cells after caffeine treatment at concentrations of 0, 1, 10, and 50 μm at extracellular calcium.

Figure 1. TAK-448 structure (A) and effect on the hypothalamic-pituitary-gonadal axis (B). At the normal physiological state, GnRH pulses in the hypothalamus.

Predicted values and SEs were based on linear mixed models

Figure 1. Melatonin levels in CSF of control subjects (n = 82) and AD patients (n = 85). *, P< Decreased Melatonin Levels in Postmortem Cerebrospinal.

FIG. 1 Odds ratios (95% CIs) of metabolic syndrome and individual components calculated for clinical measures of periodontal disease (A and B). For gingival.

Copyright © 2002 American Medical Association. All rights reserved.

Figure 1. BRAF V600E mutation analysis in PTC

Fig. 3. Mean body weight of women randomized to low-carbohydrate and low-fat diets over the course of the 4-month trial. The first time point (wk 1) represents.

Figure 1. Height distribution for adults with AIS.

Figure 1. Serum concentrations of IGF-I (A), IGF-II (B), IGFBP-3 (C), and ALS (D) throughout life in GHD (closed circles) and healthy control (open circles)

From: Is Age a Risk Factor for Hypothyroidism in Pregnancy

Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.

Triangles and dotted lines are for mean values. , P <

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Fig. 4. Relationships of changes in CRP or SAA to changes in body weight and insulin resistance. For each comparison the regression line is shown (solid.

Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.

Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse.

Fig. 1. Serum levels of IGF-I vs

High Prevalence of Vitamin D Inadequacy and Implications for Health

Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai

High Prevalence of Vitamin D Inadequacy and Implications for Health

Rajiv Agarwal, John W. Kusek, Maria K. Pappas Kidney International

Figure 2. EZO levels in infants and young children compared to adults at similar doses EZO levels in infants and young children compared to adults at similar.

Volume 77, Issue 5, Pages (March 2010)

Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents Peter de Vries, Jack.

GH dose 12 months of treatment 24 months of treatment Low Medium High

Height velocity (cm/yr) Height velocity (cm/yr)

Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15

Change in LBM (%)‏ LD CD LD CD LD CD

Volume 79, Issue 5, Pages (March 2011)

Figure 1. Randomization and dropouts.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

--- 6-months’ therapy months’ therapy Supplementary Figure 1.

Presentation transcript:

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n = 21, 25, and 25, respectively) (P < .001 within groups; *, P = .19 among groups). Bottom panel shows net gain in height (cm) in the same three groups (*, P = .01 among groups; **, P = .002 between AI and AI/GH groups). Average height and net gain in height of young men of similar ages with height SDS −2.0 are shown for comparison on the far right bars (CDC data). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12):4984-4993. doi:10.1210/jc.2016-2891 J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

Figure 1 Changes in mean (SE) height SDS (top panel) and bone age (bottom panel) over 24 months in the groups treated with AIs, GH, and AI/GH. *, P < .0012 (top panel); and **, P = .002 (bottom panel) represent the probability of difference in mean changes between groups for all parameters (ANCOVA). n = 76 (baseline), 72 (12 months), and 65 (24 months). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12):4984-4993. doi:10.1210/jc.2016-2891 J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

Figure 3 Changes in FFM (top panel) and percentage fat mass (%FM) (bottom panel) over 24 months in the AI, GH, and AI/GH groups by DXA [mean (SE)]. FFM, P < .001 within each group; *, P = .015 among groups; %FM, P = .50. AI, 0.0012; GH, < .0001; AI/GH, **, P = .003 among groups. n = 76 (baseline), 72 (12 months), 63 (24 months). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12):4984-4993. doi:10.1210/jc.2016-2891 J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society

Figure 4 Changes in mean (SE) concentrations of T (top panel), estradiol (middle panel), and IGF-1 (bottom panel) in the AI, GH, and AI/GH groups (*, P < .0001 among groups for T and IGF-1; **, P < .001 for estradiol). n = 76 (baseline), 72 (12 months), 65 (24 months). From: Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature J Clin Endocrinol Metab. 2016;101(12):4984-4993. doi:10.1210/jc.2016-2891 J Clin Endocrinol Metab | Copyright © 2016 by the Endocrine Society